First-of-its-kind(1) contact lens delivers superior visual performance(2) with seamless adaptation to light day and night(3)
The UK is the first market in EMEA to make the contact lens widely available amidst findings that 70% of Britons' eyes are bothered by light(4)
LONDON, Nov. 19, 2019 /PRNewswire/ -- Johnson & Johnson Vision* today announced the national availability of ACUVUE OASYS with Transitions Light Intelligent Technology in the UK. The first-of-its-kind1 photochromic contact lens offers superior visual performance indoor and outdoor, day and night.†
Named one of TIME magazine's best inventions‡, ACUVUE OASYS with Transitions combines the proven comfort and vision performance of ACUVUE OASYS5, with the ability to reduce the stressful impact that light can have on your eyes++3. The lens also reduces halos and starbursts around bright lights at night, delivering more effortless sight with less squinting.6++
A recent survey commissioned by Johnson & Johnson Vision found 70% of Britons' eyes are bothered by light, which can result in feelings of eye tiredness, distraction and discomfort. The survey revealed driving is the most common situation causing Brits to be bothered by light (56%), followed by the change of moving from dark to light environments, such as leaving a cinema or shopping centre (51%).
The awareness of the impact of light on eye health is also growing, with half of UK respondents (52%) indicating they are concerned about the impact of light on their eyes.
In response, 94% of UK adults who are bothered by light are turning to solutions to cope and protect their eyes, by shading their eyes (74%), squinting (71%) and turning down screen brightness (47%).
Speaking about the new product, Jakob Sveen, Director Northern European Cluster and General Manager UK & Ireland, Johnson & Johnson Vision said: "We are excited to bring ACUVUE OASYS with Transitions Light Intelligent Technology to the UK. In Europe, 64% of those who stop wearing reusable contact lenses do so because of performance and comfort issues7. Consumers are demanding more from their contact lenses beyond improved sight alone - which is what makes this contact lens so great. We believe this technology will be a game changer for the health and eye care industries, giving contact lens wearers superior visual performance over any other contact lens on the market."
The creation of the ground-breaking lens follows more than a decade of work by Johnson & Johnson Vision in partnership with Transitions Optical Limited, the leading provider of photochromic (smart adaptive) eyeglass lenses worldwide. The two organisations are working together to research and deliver best-in-class vision care innovations.
Johnson & Johnson Vision is collaborating with UK influencers and athletes, such as marathon runner Matt Rees, to share how light affects their eyes and visual performance every day, and the benefits that ACUVUE OASYS with Transitions can bring to a range of situations, whether it is commuting in and out of the office, attending an event, playing sports or driving at night.
ACUVUE OASYS with Transitions is a two-week reusable contact lens. It is now commercially available at select retailers in the UK and is being rolled-out to other markets in EMEA. Anyone interested in the lens should speak with an eye care practitioner for a prescription. For more information or to find an eye care professional near you, visit https://www.acuvue.co.uk. Follow the conversation on Instagram and Facebook.
Survey Methodology
Johnson & Johnson Vision Care Inc. and TRUE Global Intelligence, the in-house research practice of FleishmanHillard, conducted a 10-minute online survey among a nationally representative sample of 1,047 UK adults, 18 years of age and older, from 19 February through 13 March, to explore the prevalence of light sensitivity among consumers. The margin of error is +/-3 percent at a 95% confidence level.
About Johnson & Johnson Vision
At Johnson & Johnson Vision, part of Johnson & Johnson Medical Devices Companies**, we have a bold ambition: to change the trajectory of eye health around the world. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better and live better. Visit us at www.jnjvisioncare.co.uk/. Follow @JNJVision on Twitter and Johnson & Johnson Vision on LinkedIn.
About Johnson & Johnson Medical Devices Companies
As the world's most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics, vision and interventional solutions, we're working to profoundly change the way care is delivered. We are in this for life.
**Comprising the surgery, orthopaedics, vision and interventional businesses within the Johnson & Johnson's Medical Devices segment
Important Information for Contact Lens Wearers: ACUVUE Brand Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and lens care instructions provided by your optician. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your optician immediately. For more information on proper wear, care and safety, talk to your eye care professional and ask for a Patient Instruction Guide, call 0800 022 4222 or visit www.acuvue.co.uk
††All ACUVUE Brand Contact Lenses have Class 1 or Class 2 UV Blocking to help provide protection against transmission of harmful UV radiation to the cornea and into the eye. UV absorbing contact lenses are NOT substitutes for protective UV absorbing eyewear such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area.
The third-party trademarks used herein are trademarks of their respective owners.
ACUVUE and ACUVUE OASYS are registered trademarks of Johnson & Johnson Medical Ltd 2019. Transitions is a registered trademark, the Transitions logo, Transitions Light Intelligent Technology and Transitions Light Intelligent Lenses are trademarks of Transitions Optical, Inc. used under license by Transitions Optical Limited. 16OctUK3734
© Johnson & Johnson Vision Care (Ireland) T/A Vision Care Ireland RSC
* © Johnson & Johnson Vision Care (Ireland) T/A Vision Care Ireland RSC
† JJV Data on File 2018: Definition of ACUVUE OASYS with Transitions Light Intelligent Technology
‡ TIME recognized ACUVUE OASYS with Transitions as one of their Best Inventions of 2018.
++ Compared to ACUVUE OASYS with HYDRACLEAR PLUS
1 FDA Press Release: FDA clears first contact lens with light-adaptive technology https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm604263.htmApril 10, 2018.
2 JJV Data on File 2018. ACUVUE OASYS with TransitionsTM Light Intelligent TechnologyTM - Objective and Subjective Clinical.
3 JJV Data on File 2018. Definition of ACUVUE OASYS with Transitions Light Intelligent Technology.
4 JJV and FH TRUE Global Intelligence 2019 UK Survey
5 ACUVUE OASYS has never been beaten in comfort.www.clinicaltrials.gov is a website maintained by the NIH. The 23 clinical studies evaluated subjective comfort as a primary or secondary endpoint for ACUVUE OASYS Brand with HYDRACLEAR Plus or ACUVUE OASYS 1-Day with HydraLuxe Technology. Review conducted as of August, 2018.
6 AAO Academy 2018 Presentation: The Impact of Photochromic Contact Lenses on Daytime and Nighttime Driving Performance, John Buch, OD, FAAO. Available at: https://www.jnjvisionpro.com/sites/us/files/public/Grants/Academy/jjv_academy2018_clinicalresearchinnovations_final.pdf (page 13). November 7, 2018.
7 JJV Data on file 2019: Data substantiation for P2P Poland, Italy, Germany, France, UK and Denmark.
Logo - https://mma.prnewswire.com/media/600714/Johnson_and_Johnson_Vision_Logo.jpg
